Rolf Barth to Induction Chemotherapy
This is a "connection" page, showing publications Rolf Barth has written about Induction Chemotherapy.
Connection Strength
0.663
-
Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts. Clin Transplant. 2019 06; 33(6):e13531.
Score: 0.623
-
Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience. J Pharm Pract. 2021 Apr; 34(2):199-206.
Score: 0.040